IP Group news .

IP Group plc

Half-yearly results 2026

IP Group plc

Portfolio company Istesso starts Phase 2 clinical trial of leramistat in sarcopenia

IP Group plc

Portfolio company Enterprise Therapeutics reports positive results from Phase 2 clinical trial for cystic fibrosis

IP Group plc

Appointment of Michael Queen as Chair Designate

IP Group plc

Portfolio company First Light Fusion announces £25m successful first close of new round with investments from Starmaker One & UKAEA

IP Group plc

IP Group announces new fund with Australia’s Clean Energy Finance Corporation to support Australian cleantech companies

IP Group plc

Annual results 2025

IP Group plc

Portfolio company Oxa raises $103m in Series D first close, backed by National Wealth Fund and leading investors

IP Group plc

Portfolio company Microbiotica announces impressive results in its Phase 1b trial of MB310 in Ulcerative Colitis

IP Group plc

Board change